The latest data on posaconazole;Actualités sur le posaconazole

Medecine et Maladies Infectieuses

Volumn 37, Issue 2, 2007, Pages 71-76

  Paugam, A ^a  

^a hopital Cochin ^*  (France)

Author keywords

Antifungal; Posaconazole

Indexed keywords

AMIODARONE; AMPHOTERICIN B; ANTIFUNGAL AGENT; BENZNIDAZOLE; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; NIFURTIMOX; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE; ANTITRYPANOSOMAL AGENT; TRIAZOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ASPERGILLOSIS; CANCER CHEMOTHERAPY; CHROMOMYCOSIS; COCCIDIOIDOMYCOSIS; DRUG ACTIVITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EUROPE; FUNGUS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION PREVENTION; LEISHMANIASIS; LEUKEMIA REMISSION; LICENCE; MOULD; MUCORMYCOSIS; MYCETOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; RECIPIENT; REMISSION; REVIEW; TREATMENT INDICATION; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS; YEAST; ZYGOMYCETES; ADULT; ANIMAL; ANTIBIOTIC RESISTANCE; CENTRAL NERVOUS SYSTEM INFECTION; CHAGAS DISEASE; CHEMISTRY; CLINICAL TRIAL; DRUG SCREENING; IMMUNE DEFICIENCY; MOUSE; PREMEDICATION;

ADULT; ANIMALS; ANTIFUNGAL AGENTS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; CHAGAS CARDIOMYOPATHY; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, FUNGAL; HUMANS; IMMUNOCOMPROMISED HOST; MICE; MYCOSES; PREMEDICATION; TRIAZOLES; TRYPANOCIDAL AGENTS;

EID: 33847349296     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2006.11.002     Document Type: Review

References (65)

1. Xiao L., Madison V., Chau A.S., Loebenberg D., Palermo R.E., and McNicholas P.M. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14-alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48 2 (2004) 568-574
2. Munayyer H.K., Mann P.A., Chau A.S., Yarosh-Tomaine T., Greene J.R., Hare R.S., et al. Posaconazole is a potent inhibitor of sterol 14-alpha-demethylation in yeasts and molds. Antimicrob. Agents Chemother. 48 10 (2004) 3690-3696
3. Courtney R., Wexler D., Radwanski E., Lim J., and Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57 2 (2004) 218-222
4. Ezzet F., Wexler D., Courtney R., Krishna G., Lim J., and Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44 2 (2005) 211-220
5. Lewis J, et al. 15th ISHAM; 2003; abstract 256.
6. Courtney R., Radwanski E., Lim J., and Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother. 48 3 (2004) 804-808
7. Courtney R., Pai S., Laughlin M., Lim J., and Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47 9 (2003) 2788-2795
8. Keating G.M. Posaconazole. Drugs 65 11 (2005) 1553-1567
9. Groll A.H., and Walsh T.J. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev. Anti Infect. Ther. 3 4 (2005) 467-487
10. Courtney R., Sansone A., Smith W., Marbury T., Statkevich P., Martinho M., et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol. 45 2 (2005) 185-192
11. Aperis G., and Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin. Investig. Drugs 15 6 (2006) 579-602
12. Torres H.A., Hachem R.Y., Chemaly R.F., Kontoyiannis D.P., and Raad I.I. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 5 12 (2005) 775-785
13. Wexler D., Courtney R., Richards W., Banfield C., Lim J., and Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci. 21 5 (2004) 645-653
14. Raad I.I., Graybill J.R., Bustamante A.B., Cornely O.A., Gaona-Flores V., Afif C., et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin. Infect. Dis. 42 12 (2006) 1726-1734
15. Ullmann A.J., Cornely O.A., Burchardt A., Hachem R., Kontoyiannis D.P., Topelt K., et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50 2 (2006) 658-666
16. Sabatelli F., Patel R., Mann P.A., Mendrick C.A., Norris C.C., Hare R., et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50 6 (2006) 2009-2015
17. National Committee for Laboratory Standards 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved Standard M38-A. National Committee for Laboratory Standards, Waye, Pa.
18. National Committee for Laboratory Standards 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A2(22). National Committee for Laboratory Standards, Waye, Pa.
19. Cuenca-Estrella M., Gomez-Lopez A., Buitrago M.J., Mellado E., Garcia-Effron G., and Rodriguez-Tudela J.L. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob. Agents Chemother. 50 6 (2006) 2248-2250
20. Ramos G., Cuenca-Estrella M., Monzon A., and Rodriguez-Tudela J.L. In vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J. Antimicrob. Chemother. 44 2 (1999) 283-286
21. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., Garcia-Effron G., and Rodriguez-Tudela J.L. In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob. Agents Chemother. 48 8 (2004) 3107-3111
22. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., and Diekema D.J. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46 6 (2002) 1723-1727
23. Pfaller M.A., Messer S.A., Boyken L., Tendolkar S., Hollis R.J., and Diekema D.J. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the Artemis Antifungal Surveillance Program conducted in 2001 and 2002. J. Clin. Microbiol. 42 7 (2004) 3142-3146
24. Pfaller M.A., Messer S.A., Hollis R.J., and Jones R.N. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from Sentry Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. 46 4 (2002) 1032-1037
25. Perfect J.R., Cox G.M., Dodge R.K., and Schell W.A. In vitro and in vivo efficacies of the azole SCH-56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 40 8 (1996) 1910-1913
26. Pfaller M.A., Messer S.A., Boyken L., Rice C., Tendolkar S., Hollis R.J., et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43 5 (2005) 2163-2167
27. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., Buitrago M.J., Monzon A., and Rodriguez-Tudela J.L. Head-to-head comparison of the activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50 3 (2006) 917-921
28. Manavathu E.K., Cutright J.L., Loebenberg D., and Chandrasekar P.H. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH-56592). J. Antimicrob. Chemother. 46 2 (2000) 229-234
29. Espinel-Ingroff A., Chaturvedi V., Fothergill A., and Rinaldi M.G. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J. Clin. Microbiol. 40 10 (2002) 3776-3781
30. Pastor F.J., and Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin. Microbiol. Infect. 12 10 (2006) 948-960
31. Cacciapuoti A., Loebenberg D., Corcoran E., Menzel Jr. F., Moss Jr. E.L., Norris C., et al. In vitro and in vivo activities of SCH-56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. 44 8 (2000) 2017-2022
32. Graybill J.R., Hernandez S., Bocanegra R., and Najvar L.K. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob. Agents Chemother. 48 10 (2004) 3715-3719
33. Kirkpatrick W.R., McAtee R.K., Fothergill A.W., Loebenberg D., Rinaldi M.G., and Patterson T.F. Efficacy of SCH-56592 in a rabbit model of invasive aspergillosis. Antimicrob. Agents Chemother. 44 3 (2000) 780-782
34. Graybill J.R., Bocanegra R., Najvar L.K., Luther M.F., and Loebenberg D. SCH 56592 treatment of murine invasive aspergillosis. J. Antimicrob. Chemother. 42 4 (1998) 539-542
35. Walsh T.J., Petraitis V., Petraitiene R., Field-Ridley A., Sutton D., Ghannoum M., et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188 2 (2003) 305-319
36. Imai J.K., Singh G., Clemons K.V., and Stevens D.A. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob. Agents Chemother. 48 10 (2004) 4063-4066
37. McLellan G.J., Aquino S.M., Mason D.R., Kinyon J.M., and Myers R.K. Use of posaconazole in the management of invasive orbital aspergillosis in a cat. J. Am. Anim. Hosp. Assoc. 42 4 (2006) 302-307
38. Andes D., Marchillo K., Conklin R., Krishna G., Ezzet F., Cacciapuoti A., et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother. 48 1 (2004) 137-142
39. Al-Abdely H.M., Najvar L., Bocanegra R., Fothergill A., Loebenberg D., Rinaldi M.G., et al. SCH-56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"). Antimicrob. Agents Chemother. 44 5 (2000) 1159-1162
40. Barchiesi F., Schimizzi A.M., Caselli F., Giannini D., Camiletti V., Fileni B., et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J. Antimicrob. Chemother. 48 6 (2001) 769-773
41. Lozano-Chiu M., Arikan S., Paetznick V.L., Anaissie E.J., Loebenberg D., and Rex J.H. Treatment of murine fusariosis with SCH-56592. Antimicrob. Agents Chemother. 43 3 (1999) 589-591
42. Connolly P., Wheat J., Schnizlein-Bick C., Durkin M., Kohler S., Smedema M., et al. Comparison of a new triazole antifungal agent, SCH-56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother. 43 2 (1999) 322-328
43. Connolly P., Wheat L.J., Schnizlein-Bick C., Durkin M., Kohler S., Smedema M., et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob. Agents Chemother. 44 10 (2000) 2604-2608
44. Dannaoui E., Meletiadis J., Mouton J.W., Meis J.F., and Verweij P.E. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51 1 (2003) 45-52
45. Gonzalez G.M., Tijerina R., Najvar L.K., Bocanegra R., Rinaldi M., Loebenberg D., et al. In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob. Agents Chemother. 46 5 (2002) 1352-1356
46. Lutz J.E., Clemons K.V., Aristizabal B.H., and Stevens D.A. Activity of the triazole SCH-56592 against disseminated murine coccidioidomycosis. Antimicrob. Agents Chemother. 41 7 (1997) 1558-1561
47. Gonzalez G.M., Tijerina R., Najvar L.K., Bocanegra R., Rinaldi M.G., Loebenberg D., et al. Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob. Agents Chemother. 47 4 (2003) 1436-1438
48. Negroni R., Tobon A., Bustamante B., Shikanai-Yasuda M.A., Patino H., and Restrepo A. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev. Inst. Med. Trop. Sao Paulo 47 6 (2005) 339-346
49. Filiotou A., Velegraki A., Giannaris M., Pirounaki M., Mitroussia A., Kaloterakis A., et al. First case of Penicillium marneffei fungemia in Greece and strain susceptibility to five licensed systemic antifungal agents and posaconazole. Am. J. Med. Sci. 332 1 (2006) 43-45
50. Restrepo A., Tobon A., Clark B., Graham D.R., Corcoran G., Bradsher R.W., et al. Salvage treatment of histoplasmosis with posaconazole. J. Infect. (2006)
51. Wheat L.J., Connolly P., Smedema M., Durkin M., Brizendine E., Mann P., et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J. Antimicrob. Chemother. 57 6 (2006) 1235-1239
52. Hachem R.Y., Kontoyiannis D.P., Boktour M.R., Afif C., Cooksley C., Bodey G.P., et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101 7 (2004) 1594-1600
53. Walsh T.J., Raad I., Patterson T.F., Chandrasekar P., Donowitz G.R., Graybill, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Inf. Dis. 44 1 (2007) 2-12
54. Greenberg R.N., Mullane K., van Burik J.A., Raad I., Abzug M.J., Anstead G., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50 1 (2006) 126-133
55. van Burik J.A., Hare R.S., Solomon H.F., Corrado M.L., and Kontoyiannis D.P. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42 7 (2006) e61-e65
56. Tobon A.M., Arango M., Fernandez D., and Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin. Infect. Dis. 36 11 (2003) 1488-1491
57. De Decker K., Van Poucke S., Wojciechowski M., Ieven M., Colpaert C., Vogelaers D., et al. Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis. Pediatr. Crit. Care Med. 7 5 (2006) 482-485
58. Rutar T., and Cockerham K.P. Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am. J. Ophthalmol. 142 1 (2006) 187-188
59. Raad I.I., Hachem R.Y., Herbrecht R., Graybill J.R., Hare R., Corcoran G., et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42 10 (2006) 1398-1403
60. Sponsel W.E., Graybill J.R., Nevarez H.L., and Dang D. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br. J. Ophthalmol. 86 7 (2002) 829-830
61. Pitisuttithum P., Negroni R., Graybill J.R., Bustamante B., Pappas P., Chapman S., et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. 56 4 (2005) 745-755
62. Silva D.T., de Nazareth S., Almeida D., Urbina J.A., and Pereira M.C. Cytoskeleton reassembly in cardiomyocytes infected by Trypanosoma cruzi is triggered by treatment with ergosterol biosynthesis inhibitors. Int. J. Antimicrob. Agents 27 6 (2006) 530-537
63. Benaim G., Sanders J.M., Garcia-Marchan Y., Colina C., Lira R., Caldera A.R., et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J. Med. Chem. 49 3 (2006) 892-899
64. Molina J., Martins-Filho O., Brener Z., Romanha A.J., Loebenberg D., and Urbina J.A. Activities of the triazole derivative SCH-56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob. Agents Chemother. 44 1 (2000) 150-155
65. Al-Abdely H.M., Graybill J.R., Loebenberg D., and Melby P.C. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob. Agents Chemother. 43 12 (1999) 2910-2914